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Abstract
Background: Cluster headache (CH) is a debilitating condition that is generally associated with substantial health
care costs. Few therapies are approved for abortive or prophylactic treatment. Results from the prospective,
randomised, open-label PREVA study suggested that adjunctive treatment with a novel non-invasive vagus
nerve stimulation (nVNS) device led to decreased attack frequency and abortive medication use in patients
with chronic CH (cCH). Herein, we evaluate whether nVNS is cost-effective compared with the current standard of care
(SoC) for cCH.
Methods: A pharmacoeconomic model from the German statutory health insurance perspective was developed to
estimate the 1-year cost-effectiveness of nVNS + SoC (versus SoC alone) using data from PREVA. Short-term treatment
response data were taken from the clinical trial; longer-term response was modelled under scenarios of response
maintenance, constant rate of response loss, and diminishing rate of response loss. Health-related quality of life was
estimated by modelling EQ-5D™ data from PREVA; benefits were defined as quality-adjusted life-years (QALY). Abortive
medication use data from PREVA, along with costs for the nVNS device and abortive therapies (i.e. intranasal
zolmitriptan, subcutaneous sumatriptan, and inhaled oxygen), were used to assess health care costs in the
German setting.
Results: The analysis resulted in mean expected yearly costs of €7096.69 for nVNS + SoC and €7511.35 for
SoC alone and mean QALY of 0.607 for nVNS + SoC and 0.522 for SoC alone, suggesting that nVNS generates
greater health benefits for lower overall cost. Abortive medication costs were 23 % lower with nVNS + SoC
than with SoC alone. In the alternative scenarios (i.e. constant rate of response loss and diminishing rate of
response loss), nVNS + SoC was more effective and cost saving than SoC alone.
Conclusions: In all scenarios modelled from a German perspective, nVNS was cost-effective compared with
current SoC, which suggests that adjunctive nVNS therapy provides economic benefits in the treatment of
cCH. Notably, the current analysis included only costs associated with abortive treatments. Treatment with
nVNS will likely promote further economic benefit when other potential sources of cost savings (e.g. reduced
frequency of clinic visits) are considered.
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Background
Cluster headache (CH) is a debilitating condition associ-
ated with intense pain and cranial autonomic symptoms,
which cause marked disability [1]. The disorder ad-
versely affects quality of life [2] and is associated with
substantial health care costs (more than €11,000 per
year) [3]. The condition can be chronic or episodic. Both
direct costs (e.g. medication, clinic visits) and indirect
costs (e.g. reduced work capacity) have been found to be
substantially higher for patients with chronic CH (cCH)
than for those with episodic CH [3]. Few drugs (e.g.
subcutaneous [SC] sumatriptan, intranasal [IN] zolmi-
triptan, and dihydroergotamine [DHE] injection) are ap-
proved by various regulatory agencies for abortive
treatment [4, 5]. Lithium is approved for CH prophylaxis
in Germany [6] and is used off-label in other areas.
Other agents such as verapamil and topiramate are also
used off-label despite a lack of rigorous, well-controlled
studies to support their use in the prevention of CH at-
tacks [7–9]. Although short-term methylprednisone
therapy may be effective in CH prophylaxis, several
safety concerns preclude its long-term use [8].
Vagus nerve stimulation (VNS) is a neuromodulatory
technique that is well established for epilepsy and depres-
sion and has been applied to a variety of other disorders
including Alzheimer disease, migraine, and CH [10–12]. It
is thought to suppress pain through inhibition of vagal af-
ferents in the trigeminal nucleus caudalis (TNC) [13] and
by blocking or reversing increases in TNC glutamate
levels [14]; VNS has also been implicated in modulation of
the cholinergic anti-inflammatory pathway [15–17].
In an initial open-label study (N = 19), non-invasive
vagus nerve stimulation (nVNS) was found to be effective
in the prevention and treatment of CH [11]. Subsequently,
a larger (N = 97), prospective, open-label, randomised
study (PREVA [18]) evaluated the safety and efficacy of ad-
junctive treatment with a novel nVNS device (gamma-
Core®) in patients with cCH. In the PREVA trial,
compared with standard of care (SoC) alone, adjunctive
nVNS (nVNS + SoC) was associated with significantly
greater decreases from baseline in the number of CH
attacks per week and the use of abortive medications.
Compared with SoC alone, nVNS + SoC was also asso-
ciated with a significantly higher response rate (i.e. the
proportion of participants with a ≥50 % reduction from
baseline in the number of CH attacks per week; 40 %
for nVNS + SoC vs 8.3 % for SoC alone, P < 0.001) and
significantly greater improvements from baseline in
quality-of-life measures, with no serious treatment-
related adverse events.
The present analysis was undertaken to quantify the
economic impact of nVNS therapy in patients with cCH.
By developing a pharmacoeconomic model and applying
it to data from the PREVA study, we evaluated whether
nVNS is a cost-effective treatment option compared
with the current standard practice in a European set-
ting. Analysis using German costs is the focus of this
paper because Germans represented the largest propor-
tion of PREVA participants. To corroborate our find-
ings and widen their applicability, we conducted a
similar analysis using UK costs, which is briefly de-
scribed in the Discussion section.
Methods
Study design
The principal data source for this analysis was the PREVA
study (clinicaltrials.gov identifier NCT01701245), which
compared the effectiveness of nVNS added to SoC with
that of SoC alone as prophylactic therapy for cCH. For
each participant, SoC was individualised and typically in-
cluded prophylactic medications (e.g. verapamil, lithium)
and abortive agents (e.g. inhaled oxygen, triptans). The
study design (Fig. 1) and methodology of PREVA have
been described in detail previously [18]. The PREVA study
was conducted in accordance with the principles and
requirements of the Declaration of Helsinki, Good
Fig. 1 PREVA study [18] design. Abbreviations: nVNS non-invasive vagus nerve stimulation, SoC standard of care
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Clinical Practices, and clinical trial registration. All
PREVA investigators obtained institutional review board
approval, and all PREVA participants provided written
informed consent.
Model structure and parameter estimates
Figure 2 depicts the 1-year model that was used to esti-
mate the cost-effectiveness of adjunctive nVNS therapy
from the German statutory health insurance perspective.
Model parameter estimates were derived from data on
the efficacy of nVNS and the use of abortive medications
from the randomised phase of PREVA. Treatment re-
sponse was defined as ≥50 % reduction from baseline in
the number of CH attacks per week. Beyond the rando-
mised phase, responders in the SoC group were assumed
to be non-responders, and non-responders in the nVNS
+ SoC group were assumed to discontinue prophylactic
treatment with nVNS but continue use of abortive treat-
ments. Four late responders in the nVNS + SoC group
(i.e. patients who were not classified as responders
during the randomised phase but responded during the
extension phase) were included as responders in the
base case. An alternative scenario in which the 4 late re-
sponders were classified as non-responders was also
modelled in a sensitivity analysis.
To estimate the probability of response in the base
case analysis, subjects from the nVNS + SoC group who
were responders throughout the extension phase were
assumed to maintain this response until the end of the
model time horizon (1 year). In addition to the base case
analysis, 3 alternative scenarios were explored. An expo-
nential survival curve function was fitted to data from
patients in the nVNS + SoC group on the basis of their
response statuses at the end of the randomised phase
and at the end of the extension phase. In the first alter-
native scenario, the exponential function was used to
predict patient response status beyond 4 weeks (i.e.
beyond the randomised phase) assuming a constant
monthly rate (~31 %) of response loss throughout the
course of the model. The second scenario was modelled
assuming a diminishing rate of response loss; that is, the
rate at which response was lost beyond 4 weeks (as pre-
dicted by the exponential function) was reduced by a
fixed percentage (10 %) each month. In the final sce-
nario, no patients in the SoC-alone group were assumed
to have responded initially, and all other assumptions
were the same as in the base case.
Benefits in this analysis were defined as quality-
adjusted life-years (QALY). Health-related quality of
life (HRQoL) for responders and non-responders was
estimated by modelling EQ-5D™ index data from
PREVA in an ordinary least squares regression analysis
to control for potential imbalances at baseline between
treatment arms. Results from the regression analysis
suggested that response was associated with an in-
crease of 0.2366 in EQ-5D index score and that nVNS
therapy (regardless of response) was associated with
an increase of 0.01246 in EQ-5D index score. Using
the German tariff, HRQoL utility scores were esti-
mated for responders and non-responders and applied
to the model states (the UK tariff was applied for the
UK analysis).
Data on abortive medication use from the last 14 days
of the PREVA randomised phase (Table 1) were used to
Fig. 2 Pharmacoeconomic model structure. Response was defined as a ≥50 % reduction from baseline in the number of CH attacks during the
randomised period (or during month 2 in the case of 4 late responders). Responders in the SoC group were modelled as non-responders beyond
the randomised phase. Probability of response was modelled for the base case (response maintained) and for the following alternative scenarios:
1) constant rate of response loss, 2) diminishing rate of response loss, and 3) no initial response in the SoC group. Abbreviations: CH cluster headache;
SoC standard of care
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assess health care resource utilisation. Patients in the
nVNS + SoC group who maintained responder status
were assumed to continue using the same amount of re-
sources as those observed in the overall nVNS + SoC
group during the randomised phase. Non-responders
were assumed to have the same resource use as that ob-
served in the SoC group during the randomised phase.
Unit costs for nVNS, triptans, and inhaled oxygen are
shown in Table 2. The nVNS use cost was the listed
price in Germany, and unit costs for IN zolmitriptan
and SC sumatriptan were determined from the Lauer-
Taxe® [19]. Costs for inhaled oxygen were derived using
the estimated daily cost for oxygen from a previous
study [3] and data from the baseline phase of PREVA.
All economic models are associated with uncertainty;
we used a conventional method to reflect this in the
analysis by developing a probabilistic model using a
Markov chain Monte Carlo simulation to quantify how
parameter uncertainty affects model results (i.e. the
cost-effectiveness estimates for nVNS + SoC) [20, 21]
(Table 3). Distributions for each model parameter of
interest were estimated in line with best practice. A
probabilistic analysis with 1000 simulations for each sce-
nario was conducted, and mean values from this analysis
were calculated. Each simulation was plotted on the
cost-effectiveness plane to show the spread of results.
Results
Base case
For the German base case, the analysis resulted in mean
expected costs of €7096.69 for nVNS + SoC and
€7511.35 for SoC alone and mean QALY of 0.607 for
nVNS + SoC and 0.522 for SoC alone. Thus, nVNS +
SoC appears to generate greater health benefits for lower
overall cost (Table 4). Approximately 80 % of the prob-
abilistic simulations resulted in cost savings for nVNS +
SoC (versus SoC alone), and the vast majority of the
simulations plotted fell below the commonly used
€20,000/QALY gained threshold (i.e. the amount that
commissioners of health care services are willing to pay
per additional unit of health with new technologies)
Table 1 Abortive medication use during the last 14 days of the
PREVA randomised phase
Abortive medication No. of uses, mean (SD)
nVNS + SoC (n = 45) SoC alone (n = 48)
IN zolmitriptan 1.6 (5.5) 1.3 (3.6)
SC sumatriptan 2.8 (4.0) 7.5 (9.6)
Inhaled oxygen 6.5 (11.1) 10.8 (15.3)
Abbreviations: IN intranasal, nVNS non-invasive vagus nerve stimulation,
SC subcutaneous, SD standard deviation, SoC standard of care
Table 2 Unit cost of treatments
Treatment Description Cost per dose, €
IN zolmitriptan AscoTop® Nasal 5 mg/Dosis
Nasenspray, Solution €86.22:
6 single-dose nasal sprays,
PZN 03107201
14.07a
SC sumatriptan Sumatriptan-Hormosan Inject




Inhaled oxygen Estimated cost per CH attack 2.87
nVNS gammaCore device pre-loaded
with 300 stimulations
0.87
Abbreviations: IN intranasal, nVNS non-invasive vagus nerve stimulation,
SC subcutaneous
aPrices include mandatory pharmacy discount of €1.77 per pack
Published prices for zolmitriptan and sumatriptan were taken from Lauer-Taxe
(cheapest available price selected) [19]. Price for oxygen was estimated using
daily cost from Gaul et al [3]
Table 3 Parameters for the probabilistic sensitivity analysis
Parameter Mean SE Distribution
Probability of response with
nVNS + SoC
0.489 0.074 Beta
Probability of response with
SoC alone
0.083 0.039 Beta
Probability of discontinued response 0.310 0.378 Normala
Utility score (nVNS + SoC responder) 0.772 NA Multivariate normal
Utility score (nVNS + SoC
non-responder)
0.536 NA Multivariate normal
Utility score (SoC alone responder) 0.760 NA Multivariate normal
Utility score (SoC alone
non-responder)
0.523 NA Multivariate normal
Resource use per 14 days
With nVNS + SoC
Zolmitriptan 1.6 0.82 Gamma
Sumatriptan 2.8 0.60 Gamma
Oxygen 6.5 1.65 Gamma
With SoC alone
Zolmitriptan 1.3 0.52 Gamma
Sumatriptan 7.5 1.38 Gamma
Oxygen 10.8 2.21 Gamma
Abbreviations: NA not applicable, nVNS non-invasive vagus nerve stimulation,
SE standard error, SoC standard of care
aBased on exponential survival function
Table 4 Base casea cost-effectiveness analysis
Treatment group Mean cost, € Mean QALY ICERb
nVNS + SoC 7096.96 0.607 nVNS dominant
over SoCc
SoC alone 7511.35 0.522
Abbreviations: ICER incremental cost-effectiveness ratio, nVNS non-invasive
vagus nerve stimulation, QALY quality-adjusted life-year, SoC standard of care
Probabilistic estimates are based on mean results across all Monte Carlo
simulations [21]
aIn the base case, subjects in the nVNS + SoC group who responded through
the extension phase were assumed to maintain response
bThe expense of gaining an additional QALY with adjunctive nVNS therapy
(vs SoC alone)
cIndicates that adjunctive nVNS therapy was more effective and cost saving
than SoC alone
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(Fig. 3) [22–24]. Overall abortive medication costs were
23 % lower in the nVNS + SoC group than in the SoC-
alone group (Fig. 4). Compared with the SoC-alone group,
the nVNS + SoC group had 29 % lower SC sumatriptan
costs, 19 % lower inhaled oxygen costs, and 75 % higher
IN zolmitriptan costs.
Alternative scenarios and sensitivity analysis
Altering the model by varying the likelihood for loss of
response in either group had little effect on the relative
cost-effectiveness of nVNS (Table 5). In the alternative
scenarios explored, the percentages of the probabilistic
simulations that resulted in cost savings for nVNS + SoC
(versus SoC alone) were ~71 % for constant rate of
response loss and ~79 % for both diminishing rate of
response loss and no response for SoC. Results from the
sensitivity analysis suggest that exclusion of the 4 late
responders to nVNS (i.e. designating them as non-
responders in the model) had a modest impact on cost-
effectiveness. For all scenarios modelled in the sensitivity
analysis, nVNS + SoC was more effective and cost saving
(Table 6).
Discussion
The treatment of CH is challenging, and many of the
commonly used abortive and preventive medications are
associated with serious safety risks, poor tolerability,
and/or marginal efficacy. For acute treatment, triptans
are contraindicated in patients with cardiovascular dis-
ease [25, 26]. Drug costs or restrictions on prescribing
and/or coverage may further limit triptan accessibility
for many patients [27, 28]. Long-term frequent use of
triptans, as may be needed for cCH management, can in
turn lead to the development of medication overuse
headache [29, 30], which, although rare, has been re-
ported in patients with CH [31, 32]. Oxygen may delay
rather than abort CH attacks in some patients and has
portability limitations [25, 26], and DHE may be associ-
ated with fibrosis (e.g. cardiac, pulmonary, pleural), er-
gotism, and chest tightness [26, 33]. For prophylactic
treatment, verapamil has a high potential for drug inter-
actions, and the large dosages required for CH treatment
are associated with adverse cardiac events such as ar-
rhythmias, as well as oedema [26]. Lithium requires
progressive titration and frequent drug-level monitoring
because of its narrow therapeutic window and the risk
Fig. 3 Plot of the base case model simulations (cost-effectiveness plane). Abbreviation: QALY quality-adjusted life-year
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of toxicity [25, 26, 34], and topiramate is often poorly
tolerated owing to its cognitive side effects [26]. Thus,
more practical and cost-effective treatment approaches
for CH are needed. Results from the PREVA study [18]
suggest that in addition to reducing the frequency of CH
attacks, adjunctive nVNS therapy may decrease the need
for abortive medications and improve quality of life in
patients with cCH. The current pharmacoeconomic ana-
lysis indicates that adjunctive nVNS is likely to result in
cost savings when compared with SoC alone. Notably,
the present analysis was conservative in that it included
only the costs associated with use of abortive medica-
tions without accounting for other potential sources of
cost savings (e.g. reduced frequency of clinic visits, fewer
hospitalisations, increased productivity).
Currently, there are few good options for acute or
prophylactic treatment of CH. Neuromodulation methods
such as sphenopalatine ganglion (SPG) stimulation and
occipital nerve stimulation (ONS) have shown some
promise in CH prevention, but most studies of these tech-
niques have been small and/or have lacked control arms
[35, 36]. Furthermore, SPG and ONS are invasive, expen-
sive, and associated with risks inherent with implanted
devices (e.g. infection, pain at the site of implantation,
electrode migration). The findings that nVNS is effective
in cCH prophylaxis [18], is not associated with risks that
are inherent in invasive neuromodulation methods, and
offers cost savings over the current standard practice
suggest that this therapy warrants a prominent place in
the management of cCH.
The current analysis is subject to certain limitations.
The PREVA study provided data from an 8-week period,
Fig. 4 Breakdown of modelled 1-year costs of abortive medications by category. Abbreviations: IN intranasal; nVNS non-invasive vagus nerve
stimulation; SC subcutaneous; SoC standard of care
Table 5 Cost-effectiveness analysis for alternative scenarios
Scenario
Treatment group Mean cost, € Mean QALY ICERa
Constant rate of response loss
nVNS + SoC 7377.41 0.558 nVNS dominant
over SoCb
SoC alone 7518.56 0.526
Diminishing rate of response loss
nVNS + SoC 7141.30 0.599 nVNS dominant
over SoCb
SoC alone 7508.98 0.525
No response for SoC
nVNS + SoC 7085.34 0.610 nVNS dominant
over SoCb
SoC alone 7507.94 0.524
Abbreviations: ICER incremental cost-effectiveness ratio, nVNS non-invasive
vagus nerve stimulation, QALY quality-adjusted life-year, SoC standard of care
Probabilistic estimates are based on mean results across all Monte Carlo
simulations [21]
aThe expense of gaining an additional QALY with adjunctive nVNS therapy
(vs SoC alone)
bIndicates that adjunctive nVNS therapy was more effective and cost saving
than SoC alone
Table 6 Cost-effectiveness sensitivity analysis (4 late responders
excluded)
Scenario
Treatment group Mean cost, € Mean QALY ICERa
Response maintained
nVNS + SoC 7380.93 0.566 nVNS dominant
over SoCb
SoC alone 7540.28 0.536
Constant rate of response loss
nVNS + SoC 7392.09 0.550 nVNS dominant
over SoCb
SoC alone 7440.13 0.539
Diminishing rate of response loss
nVNS + SoC 7279.89 0.560 nVNS dominant
over SoCb
SoC alone 7385.29 0.537
Abbreviations: ICER incremental cost-effectiveness ratio, nVNS non-invasive
vagus nerve stimulation, QALY quality-adjusted life-year, SoC standard of care
aThe expense of gaining an additional QALY with adjunctive nVNS therapy
(vs SoC alone)
bIndicates that adjunctive nVNS therapy was more effective and cost saving
than SoC alone
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which were extrapolated to assess cost-effectiveness over
1 year. Although there have been few cost-effectiveness
evaluations of neuromodulatory techniques for the
treatment of primary headache disorders, such studies
have generally included time horizons of at least 3 years
[37–39]. Considering the time frame of PREVA, a 1-year
time horizon was chosen for this analysis to preserve
robustness and to avoid introducing unnecessary uncer-
tainty. As in patients with epilepsy [40], evidence sug-
gests that patients with headache may have improved
response to VNS with longer-term treatment [41, 42].
Although increases in response rate with long-term VNS
have yet to be explored in CH, the current analysis could
be viewed as conservative because the duration of
PREVA may not have allowed demonstration of the full
benefit of nVNS.
Recently, the National Institute for Health and Care
Excellence (NICE) Interventional Procedures Advisory
Committee noted that the relapsing/remitting nature of
CH and migraines as well as the potential for placebo
effects should be considered when interpreting evidence
of treatment efficacy for these conditions [43]. Indeed,
because periods of relapse and remission are common
among patients with primary headache disorders, re-
search in this area may be susceptible to regression arte-
facts [44, 45]. However, the PREVA study included data
from patients with cCH only. By International Classifi-
cation of Headache Disorders definition [46], cCH is not
associated with extended periods of remission (i.e.
≥1 month), suggesting that the phenomenon of regres-
sion to the mean (e.g. aberrantly high attack frequency
at baseline followed by a decrease in attack frequency
regardless of treatment group) would not be expected.
Because the PREVA study lacked a sham treatment
group, the degree to which the placebo effect might have
contributed to the cost-effectiveness of nVNS is unclear.
Nevertheless, the clinically relevant design of the PREVA
study was valuable in that it allowed for observation of
medication use in a control group that likely reflects
real-world use.
As with any probabilistic analysis, some degree of
uncertainty is inherent in the current investigation. To ad-
dress this, a sensitivity analysis and a range of alternative
scenarios were included, and results from all of these sug-
gested that nVNS + SoC was more effective and cost saving
than SoC alone. Results were relatively insensitive to as-
sumptions about late responders in the nVNS+ SoC arm.
In the sensitivity analysis, where the 4 late-responding
patients were classified as non-responders, nVNS + SoC
was dominant over SoC alone in all modelled scenarios.
The current analysis cannot be directly extrapolated
across all of Europe because it evaluates cost-effectiveness
from a German health insurance perspective. To explore
the generalisability of our findings, we conducted the same
analysis from a UK perspective and found similar results.
For the base case, the probabilistic analysis resulted in
mean expected costs of £5409.83 for nVNS+ SoC and
£5393.31 for SoC alone and mean QALY of 0.538 for
nVNS+ SoC and 0.438 for SoC alone. The incremental
cost-effectiveness ratio of nVNS + SoC was £166.12, and
47 % of the probabilistic simulations resulted in cost savings
for nVNS+ SoC over SoC alone (J. Morris, unpublished
data, 2016). The degree to which these results can be gener-
alised to other countries may vary depending on specific
drug prices and the availability of generic medications in
those markets.
Lastly, the current cost-effectiveness projections in-
cluded only the costs associated with the use of abortive
treatments. This suggests that our analysis is conserva-
tive, as data on additional health care resource use (e.g.
clinic visits) would likely lead to a disproportionate cost
increase for the SoC-alone group. Likewise, potential
health benefits from decreased use of abortive medica-
tions (e.g. drug-related side effects) and effects on indir-
ect costs (e.g. increased work capacity), which could
further enhance the economic profile of nVNS, were not
considered herein. The economic benefits of nVNS
could be established with greater certainty by incorpor-
ating additional cost components into future studies.
Conclusions
The current study provides evidence of the efficacy and
economic benefits of nVNS therapy for patients with
cCH in the context of the German and UK health care
systems. In all scenarios modelled, nVNS was more
cost-effective than the current standard practice. These
findings are especially meaningful given the substantial
economic burden associated with CH [3] and consider-
ing that new technologies are cited as major drivers of
increasing health care expenditures [47, 48]. Our results
suggest that new technologies such as nVNS may help
decrease overall treatment costs, information that likely
will be important to clinicians, patients, and payers when
treatment decisions are made.
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